June 10, 2014
Law360
On June 10, Ferring Pharmaceuticals asked the Federal Circuit to affirm a finding of infringement against Watson Pharmaceuticals and to reverse a decision allowing Apotex to modify a product that infringed on a Ferring patent, Lysteda, a heavy menstrual bleeding medication. Both are generic pharmaceutical companies.
Watson is appealing an infringement finding, and Ferring is seeking a rejection of this appeal. Finnegan attorney Paul W. Browning, Ph.D. told the panel that evidence clearly showed that a portion of Watson's product had infringed Ferring’s patent. “The evidence was that up to 16 percent of certain batches—undisputed evidence—infringed,” he said.
Ferring is also appealing a post-trial order from the court that allowed Apotex to change the dissolution rate of its product, which helped it avoid an infringement finding. Finnegan attorney James B. Monroe argued that the district court read a Ferring patent claim too narrowly in deciding that the dissolution rate fell outside of its patent, which says the court should have followed its expert testimony that showed the altered product still fell within the range of its patent.
Award/Ranking
Managing IP Americas Awards 2024: Finnegan Shortlisted for Nine Awards, Including Firm of the Year
March 12, 2024
Commentary
February 29, 2024
Award/Ranking
Managing IP EMEA Awards 2024: Finnegan Shortlisted for Global Firm of the Year Award
February 19, 2024
Commentary
Understanding IP Matters: The Mysteries of Design Patents – Preventing Abuse Before It Happens
February 7, 2024
Award/Ranking
U.S. News & World Report Names Finnegan One of the Best Companies to Work For
January 30, 2024
Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.
We use cookies on this website to provide you with the best user experience. By accepting cookies, you agree to our use of cookies. Please note that if you opt not to accept or if you disable cookies, the “Your Finnegan” feature on this website will be disabled as well. For more information on how we use cookies, please see our Privacy Policy.
Finnegan is thrilled to announce the launch of our new blog, Ad Law Buzz, devoted solely to breaking news, developments, trends, and analysis in advertising law.